abstract: UNASSIGNED: Common scab, a globally important @entity415 disease, is caused by @entity281 of tubers with pathogenic Streptomyces spp. Previously, disease-resistant @entity415 somaclones were obtained through cell selections against the pathogen's toxin, known to be essential for disease. Further testing revealed that these clones had broad-spectrum resistance to diverse tuber-invading pathogens, and that resistance was restricted to tuber tissues. The mechanism of enhanced disease resistance was not known. Tuber periderm tissues from disease-resistant clones and their susceptible parent were examined histologically following challenge with the pathogen and its purified toxin. Relative expression of genes associated with tuber suberin biosynthesis and innate defense pathways within these tissues were also examined. The disease-resistant somaclones reacted to both pathogen and toxin by producing more phellem cell layers in the tuber periderm, and accumulating greater suberin @entity6398 in these tissues. Furthermore, they had greater expression of genes associated with suberin biosynthesis. In contrast, signaling genes associated with innate defense responses were not differentially expressed between resistant and susceptible clones. The resistance phenotype is due to induction of increased periderm cell layers and suberization of the tuber periderm preventing @entity281 . The somaclones provide a valuable resource for further examination of suberization responses and its genetic control.

title: Toughing It Out-Disease-Resistant XXXX Mutants Have Enhanced Tuber Skin Defenses.

entities_list: @entity6398 :: ('MESH:D059808', 'Chemical') :: ['polyphenols']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

answer: @entity415 :: (4113,Species) :: ['Potato']


abstract: BACKGROUND: Approximately 20-50% of @entity1 regain weight 3-5 years after Roux-en-Y gastric bypass (RYGB) surgery. @entity356 and dilation of the gastrojejunostomy and gastric pouch have been reported in these @entity1 . Traditional revision surgery after RYGB has greater morbidity and mortality compared with the index bariatric procedure. We studied our initial results with revision of @entity28 surgery using an endoscopic platform in a community hospital setting. METHODS: A retrospective review was performed of @entity1 who had undergone this endoscopic revisional procedure secondary to significant weight regain with or without @entity356 . All @entity1 underwent revision of the gastrojejunostomy and/or closure of the @entity356 using this minimally invasive approach. RESULTS: A total of 37 consecutive @entity1 (36 @entity1 ) with a mean age of 45 years and mean weight regain of 15.1    10.0 kg were included in the present study. The mean interval between RYGB and revision was 5.2 years (range 1-11). The mean preoperative and postoperative stomal size was 21.5 and 10 mm, respectively. Anchors were successfully placed in all @entity1 . The mean follow-up period was 4.69 months (range 2-10). The mean percentage of excess body @entity353 was 23.5%    66.4%. No immediate complications developed. Two @entity1 underwent endoscopic dilation of the stoma because of persistent meal intolerance. Three @entity356 were successfully closed. CONCLUSION: Revision of gastrojejunostomy after RYGB can be safely undertaken using this endoscopic platform. The short-term follow-up results showed clinically significant @entity353 . Long-term follow-up is needed. Closure of @entity356 can also be achieved using this procedure.

title: Endolumenal revision @entity28 surgery results in XXXX and closure of @entity356 .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['Gastric-gastric fistulas', 'gastric-gastric fistula', 'gastric-gastric fistulas']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

answer: @entity353 :: (MESH:D015431,Disease) :: ['weight loss']


abstract: BACKGROUND: Approximately 20-50% of @entity1 regain weight 3-5 years after Roux-en-Y gastric bypass (RYGB) surgery. @entity356 and dilation of the gastrojejunostomy and gastric pouch have been reported in these @entity1 . Traditional revision surgery after RYGB has greater morbidity and mortality compared with the index bariatric procedure. We studied our initial results with revision of @entity28 surgery using an endoscopic platform in a community hospital setting. METHODS: A retrospective review was performed of @entity1 who had undergone this endoscopic revisional procedure secondary to significant weight regain with or without @entity356 . All @entity1 underwent revision of the gastrojejunostomy and/or closure of the @entity356 using this minimally invasive approach. RESULTS: A total of 37 consecutive @entity1 (36 @entity1 ) with a mean age of 45 years and mean weight regain of 15.1    10.0 kg were included in the present study. The mean interval between RYGB and revision was 5.2 years (range 1-11). The mean preoperative and postoperative stomal size was 21.5 and 10 mm, respectively. Anchors were successfully placed in all @entity1 . The mean follow-up period was 4.69 months (range 2-10). The mean percentage of excess body @entity353 was 23.5%    66.4%. No immediate complications developed. Two @entity1 underwent endoscopic dilation of the stoma because of persistent meal intolerance. Three @entity356 were successfully closed. CONCLUSION: Revision of gastrojejunostomy after RYGB can be safely undertaken using this endoscopic platform. The short-term follow-up results showed clinically significant @entity353 . Long-term follow-up is needed. Closure of @entity356 can also be achieved using this procedure.

title: Endolumenal revision XXXX surgery results in @entity353 and closure of @entity356 .

answer: @entity28 :: (MESH:D009765,Disease) :: ['obesity']


abstract: BACKGROUND: Approximately 20-50% of @entity1 regain weight 3-5 years after Roux-en-Y gastric bypass (RYGB) surgery. @entity356 and dilation of the gastrojejunostomy and gastric pouch have been reported in these @entity1 . Traditional revision surgery after RYGB has greater morbidity and mortality compared with the index bariatric procedure. We studied our initial results with revision of @entity28 surgery using an endoscopic platform in a community hospital setting. METHODS: A retrospective review was performed of @entity1 who had undergone this endoscopic revisional procedure secondary to significant weight regain with or without @entity356 . All @entity1 underwent revision of the gastrojejunostomy and/or closure of the @entity356 using this minimally invasive approach. RESULTS: A total of 37 consecutive @entity1 (36 @entity1 ) with a mean age of 45 years and mean weight regain of 15.1    10.0 kg were included in the present study. The mean interval between RYGB and revision was 5.2 years (range 1-11). The mean preoperative and postoperative stomal size was 21.5 and 10 mm, respectively. Anchors were successfully placed in all @entity1 . The mean follow-up period was 4.69 months (range 2-10). The mean percentage of excess body @entity353 was 23.5%    66.4%. No immediate complications developed. Two @entity1 underwent endoscopic dilation of the stoma because of persistent meal intolerance. Three @entity356 were successfully closed. CONCLUSION: Revision of gastrojejunostomy after RYGB can be safely undertaken using this endoscopic platform. The short-term follow-up results showed clinically significant @entity353 . Long-term follow-up is needed. Closure of @entity356 can also be achieved using this procedure.

title: Endolumenal revision @entity28 surgery results in @entity353 and closure of XXXX .

answer: @entity356 :: (MESH:D013274,Disease) :: ['gastric-gastric fistula']


abstract: OBJECTIVES: To characterize the site and clinical implications of intravesical recurrence after radical nephroureterectomy for upper @entity3484 . METHODS: @entity1 who underwent radical nephroureterectomy for upper @entity3484 between 2000 and 2011 at 12 institutions participating in the Tohoku Urological Evidence-Based Medicine Study Group were included in the present study. Those who underwent prior or simultaneous radical cystectomy were excluded. The site of intravesical recurrence was investigated, and the survival curves after radical nephroureterectomy were analyzed retrospectively using the Kaplan-Meier method. Multivariate analyses of factors predicting survival were carried out. RESULTS: A total of 534 @entity1 were eligible for the present study. With a median follow up of 47  months, 205 @entity1 (38.4%) had intravesical recurrence. The intravesical recurrence-free survival rates at 1, 2, and 5  years were 74.6%, 62.5% and 56.3%, respectively. In a subset of 137 @entity1 with intravesical recurrence who did not have @entity150 before or at the diagnosis of upper @entity3484 , the most frequent site of intravesical recurrence was around the cystotomy (52.6%), followed by at the posterior wall (39.4%) and at the @entity1494 (35.8%). A total of 36 @entity1 (17.6%) developed @entity150 after radical nephroureterectomy. On multivariate analyses for the subset of @entity1 with non-muscle invasive ( <= @entity2558 ) upper @entity3484 , intravesical recurrence was an independent predictor of cancer-specific survival (HR 4.27, P  =  0.016) and overall survival (HR 3.00, P  =  0.018). CONCLUSIONS: Most intravesical recurrences occur around the site of bladder @entity3137 within 1  year after radical nephroureterectomy, providing important insight into the mechanism of intravesical recurrence. Intravesical recurrence after radical nephroureterectomy had an impact on oncological outcomes of @entity1 with non-muscle invasive upper @entity3484 .

title: Clinical implications of intravesical recurrence after radical nephroureterectomy for upper XXXX .

entities_list: @entity3484 :: ('MESH:D014571', 'Disease') :: ['urinary tract urothelial carcinoma']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1494 :: ('MESH:D001745', 'Disease') :: ['bladder neck']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer', 'muscle-invasive bladder cancer']

entities_list: @entity3137 :: ('MESH:D009059', 'Disease') :: ['mucosal injury']

answer: @entity3484 :: (MESH:D014571,Disease) :: ['urinary tract urothelial carcinoma']


abstract: BACKGROUND: @entity296 after non-cardiac surgery (MINS) is closely related to increased cardiovascular mortality. AIM: Our aim was to evaluate the relationship between MINS and interarm systolic blood pressure difference (IASBPD) - which has previously been shown to correlate with the frequency of cardiovascular events and arterial arteriosclerotic processes. METHODS: This observational, single-center cohort study included 240 consecutive noncardiac surgery @entity1 aged >= 45 years. Simultaneous blood pressure recordings were taken preoperatively and IASBPD was calculated. @entity1 electrocardiography recordings and high sensitivity cardiac troponin T (hscTnT) levels were obtained for a period of 3 days postoperatively. RESULTS: Postoperatively, 27 @entity1 (11.3%) were found to have MINS when hscTnT >= 14 ng/L was taken as a cut-off value. IASBPD >10 mmHg was found in 44 @entity1 (18.3%). When IASBPD was accepted to be a continuous variable, there was a higher IASBPD value in the MINS group (9.4  5.0 vs. 4.5  3.8, p<0.000). When @entity1 were grouped as those having IASBPD>10 mmHg and those not, exaggerate IASBPD was found to be more frequent in @entity1 developing MINS (16 (59.3%) vs. 28 (13.1%) respectively, p<0.000). Multiple logistic regression analysis found IASBPD>10 mmHg to be independently associated with the development of MINS (OR: 30.82 (CI: 9.14-103.98), p<0.000). ROC curve analysis showed that the optimal IASBPD cut-off value for predicting MINS was 11.5 mmHg, with a sensitivity of 61.0% and specificity of 89.1% (AUC = 0.79; 95% CI: 0.71-0.87). CONCLUSIONS: Increased IASBPD is closely related to development of MINS. The preoperative measurement of blood pressure from both arms may be an important and easy to use clinical tool in determining cardiovascular risk.

title: Interarm systolic blood pressure difference is associated with XXXX after noncardiac surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['Myocardial injury']

answer: @entity296 :: (MESH:D009202,Disease) :: ['myocardial injury']


abstract: BACKGROUND: Since gamma interferon release assays (IGRAs) cannot differentiate between active @entity378 and @entity9178 ( @entity9178 ), development of rapid and specific diagnosis tools are essential for discriminating between active @entity378 ( @entity378 ) from @entity9178 . Both IGRAs are based on Mycobacterium @entity378 -specific antigens, namely, early secretory antigenic target 6 (ESAT-6) and 10kDa culture filtrate (CFP-10). The aim of this study was to evaluate the potential value of @entity1199 secretion by whole blood cells after stimulation with rESAT-6 and rCFP-10 for discriminating between active and @entity9178 . METHODS: @entity1199 and @entity379 were measured after blood stimulation of 90 cases (30 with active @entity378 , 30 with @entity9178 and 30 healthy controls) with recombinant ESAT-6 and CFP-10. Receiver operating characteristic (ROC) curve analysis was conducted to determine the best @entity1199 and @entity379 result thresholds in discriminating between cases with active or @entity9178 , and the corresponding sensitivity and specificity were recorded. RESULTS: The @entity379 release assay demonstrated a good sensitivity and specificity (sensitivity 83-84% and specificity 92%) for diagnosis of @entity378 . The discrimination performance of @entity1199 assay (assessed by the area under ROC curve) between @entity9178 and @entity1 with active @entity378 were 0.75 and 0.8 following stimulation with rESAT-6 and rCFP-10, respectively. Maximum discrimination was reached at a cut-off of 11.6pg/mL for @entity1199 after stimulation with recombinant rESAT-6 with 72% sensitivity and 79% specificity and 10.7pg/mL for @entity1199 following stimulation with rCFP-10 with 75% sensitivity and 79% specificity, respectively. CONCLUSION: This study demonstrates that rESAT-6 and rCFP-10 can provide a sensitive and specific diagnosis of @entity378 . In addition, it was shown that @entity1199 may be serving as a marker for discriminating @entity9178 and active @entity378 .

title: Improving T-cell assays for diagnosis of XXXX : Confirmation of the potential role of testing @entity1199 release in Iranian @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity9178 :: ('MESH:D055985', 'Disease') :: ['LTBI', 'latent tuberculosis', 'latent tuberculosis infection', 'latent TB']

entities_list: @entity378 :: ('MESH:D014376', 'Disease') :: ['TB', 'tuberculosis']

answer: @entity9178 :: (MESH:D055985,Disease) :: ['latent TB infection']


abstract: BACKGROUND: Since gamma interferon release assays (IGRAs) cannot differentiate between active @entity378 and @entity9178 ( @entity9178 ), development of rapid and specific diagnosis tools are essential for discriminating between active @entity378 ( @entity378 ) from @entity9178 . Both IGRAs are based on Mycobacterium @entity378 -specific antigens, namely, early secretory antigenic target 6 (ESAT-6) and 10kDa culture filtrate (CFP-10). The aim of this study was to evaluate the potential value of @entity1199 secretion by whole blood cells after stimulation with rESAT-6 and rCFP-10 for discriminating between active and @entity9178 . METHODS: @entity1199 and @entity379 were measured after blood stimulation of 90 cases (30 with active @entity378 , 30 with @entity9178 and 30 healthy controls) with recombinant ESAT-6 and CFP-10. Receiver operating characteristic (ROC) curve analysis was conducted to determine the best @entity1199 and @entity379 result thresholds in discriminating between cases with active or @entity9178 , and the corresponding sensitivity and specificity were recorded. RESULTS: The @entity379 release assay demonstrated a good sensitivity and specificity (sensitivity 83-84% and specificity 92%) for diagnosis of @entity378 . The discrimination performance of @entity1199 assay (assessed by the area under ROC curve) between @entity9178 and @entity1 with active @entity378 were 0.75 and 0.8 following stimulation with rESAT-6 and rCFP-10, respectively. Maximum discrimination was reached at a cut-off of 11.6pg/mL for @entity1199 after stimulation with recombinant rESAT-6 with 72% sensitivity and 79% specificity and 10.7pg/mL for @entity1199 following stimulation with rCFP-10 with 75% sensitivity and 79% specificity, respectively. CONCLUSION: This study demonstrates that rESAT-6 and rCFP-10 can provide a sensitive and specific diagnosis of @entity378 . In addition, it was shown that @entity1199 may be serving as a marker for discriminating @entity9178 and active @entity378 .

title: Improving T-cell assays for diagnosis of @entity9178 : Confirmation of the potential role of testing XXXX release in Iranian @entity1 .

answer: @entity1199 :: (3558,Gene) :: ['Interleukin-2']


abstract: BACKGROUND: Since gamma interferon release assays (IGRAs) cannot differentiate between active @entity378 and @entity9178 ( @entity9178 ), development of rapid and specific diagnosis tools are essential for discriminating between active @entity378 ( @entity378 ) from @entity9178 . Both IGRAs are based on Mycobacterium @entity378 -specific antigens, namely, early secretory antigenic target 6 (ESAT-6) and 10kDa culture filtrate (CFP-10). The aim of this study was to evaluate the potential value of @entity1199 secretion by whole blood cells after stimulation with rESAT-6 and rCFP-10 for discriminating between active and @entity9178 . METHODS: @entity1199 and @entity379 were measured after blood stimulation of 90 cases (30 with active @entity378 , 30 with @entity9178 and 30 healthy controls) with recombinant ESAT-6 and CFP-10. Receiver operating characteristic (ROC) curve analysis was conducted to determine the best @entity1199 and @entity379 result thresholds in discriminating between cases with active or @entity9178 , and the corresponding sensitivity and specificity were recorded. RESULTS: The @entity379 release assay demonstrated a good sensitivity and specificity (sensitivity 83-84% and specificity 92%) for diagnosis of @entity378 . The discrimination performance of @entity1199 assay (assessed by the area under ROC curve) between @entity9178 and @entity1 with active @entity378 were 0.75 and 0.8 following stimulation with rESAT-6 and rCFP-10, respectively. Maximum discrimination was reached at a cut-off of 11.6pg/mL for @entity1199 after stimulation with recombinant rESAT-6 with 72% sensitivity and 79% specificity and 10.7pg/mL for @entity1199 following stimulation with rCFP-10 with 75% sensitivity and 79% specificity, respectively. CONCLUSION: This study demonstrates that rESAT-6 and rCFP-10 can provide a sensitive and specific diagnosis of @entity378 . In addition, it was shown that @entity1199 may be serving as a marker for discriminating @entity9178 and active @entity378 .

title: Improving T-cell assays for diagnosis of @entity9178 : Confirmation of the potential role of testing @entity1199 release in Iranian XXXX .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: PURPOSE OF REVIEW: The purpose of this review is to summarize the current evidence for the genetic basis of stress @entity322 (SUI). RECENT FINDINGS: Based on epidemiologic data, there appears to be a genetic predisposition for the development of SUI. One thought is that there are abnormalities in expression of extracellular matrix (ECM) proteins leading to alterations in the composition of the ECM. Several studies have identified candidate genes encoding ECM proteins as well as inducers/inhibitors of these proteins, which are thought to lead to the development of SUI. Also, there is increasing evidence to suggest expression of these candidate genes may be influenced by the presence or absence of @entity172 and @entity1420 . Pelvic organ prolapse is closely related to SUI, and the genes thought to be involved in the development of @entity3577 may also be linked to the development of SUI. SUMMARY: There is increasing evidence to support a genetic basis for the development of SUI, but some of the evidence is contradictory. Several candidate genes have been identified and these may lead to alterations in the composition of the ECM, ultimately predisposing some @entity1 to develop SUI. Future studies are needed to identify other candidate genes that may be involved in SUI and to study the influence of @entity172 and @entity1420 on ECM proteins thought to be involved in SUI. The identification of genes involved in the development of SUI could lead to new therapies for the treatment of SUI.

title: Genetic influences on stress XXXX .

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen']

entities_list: @entity322 :: ('MESH:D014549', 'Disease') :: ['urinary incontinence']

entities_list: @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone']

entities_list: @entity3577 :: ('MESH:D056887', 'Disease') :: ['pelvic organ prolapse']

answer: @entity322 :: (MESH:D014549,Disease) :: ['urinary incontinence']


abstract: OBJECTIVES: Inhibins, dimeric peptide hormones composed of an a-subunit and 1 of 2 possible b subunits (bA or bB), exhibit substantial roles in @entity1 reproduction and in @entity8703 . However, it is still unclear whether normal and cancerous cervical tissues as well as @entity5 cell lines express the inhibin-bA and -bB subunits. MATERIALS AND METHODS: Normal @entity1 uterine cervical tissue was obtained from 4 premenopausal nonpregnant @entity1 . In addition, a total of 32 specimens of @entity3146 ( @entity3146 ) of different stages were obtained ( @entity3146 1 = 10, @entity3146 2 = 9, and @entity3146 3 = 13). Moreover, 30 @entity5 samples of well-differentiated (grade 1; n = 10), moderate differentiated (grade 2; n = 10), and poorly differentiated (grade 3; n = 10) grading were analyzed. RESULTS: An immunohistochemical staining reaction for inhibin-bA and -bB subunits could be observed in normal and malignant cervical tissue as well as in @entity5 cell lines. Regarding inhibin-bA significant differences were observed between normal tissue and @entity3146 1 and @entity3146 3. Moreover, the immunohistochemical staining reaction for inhibin-bA was significantly higher in @entity3146 3 compared with that in cervical @entity189 grades 1 and 2. The inhibin-bB expression was higher in @entity3146 and @entity5 compared with that in normal cervical tissue. Inhibin-bB was significantly higher in @entity3146 2 and @entity3146 3 compared with @entity5 tissues of histological grade 1. In addition, a significant increase of the staining intensity was observed between @entity5 grades 1 and 2 as well as grade 3. CONCLUSIONS: Both inhibin-b subunits demonstrated a differential expression in @entity3146 and @entity5 , suggesting important roles in cervical @entity105 . Inhibin-bA might be important during progression of @entity3146 , whereas the inhibin-bB subunit could exert a substantial function during differentiation of cervical @entity189 . Moreover, the synthesis of this subunit in cervical @entity189 cell lines also allows the use of this cell line to elucidates their functions in @entity5 pathogenesis.

title: Immunolabeling of the inhibin-bA and -bB subunit in normal and malignant @entity1 cervical tissue and XXXX cell lines.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity8703 :: ('MESH:D004701', 'Disease') :: ['endocrine-responsive tumors']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'cervical cancer', 'squamous cervical cancer', 'squamous cancer']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas', 'carcinoma']

entities_list: @entity105 :: ('MESH:D063646', 'Disease') :: ['carcinogenesis']

entities_list: @entity3146 :: ('MESH:D018290', 'Disease') :: ['cervical intraepithelial neoplasia', 'CIN']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cervical cancer']


abstract: OBJECTIVES: Inhibins, dimeric peptide hormones composed of an a-subunit and 1 of 2 possible b subunits (bA or bB), exhibit substantial roles in @entity1 reproduction and in @entity8703 . However, it is still unclear whether normal and cancerous cervical tissues as well as @entity5 cell lines express the inhibin-bA and -bB subunits. MATERIALS AND METHODS: Normal @entity1 uterine cervical tissue was obtained from 4 premenopausal nonpregnant @entity1 . In addition, a total of 32 specimens of @entity3146 ( @entity3146 ) of different stages were obtained ( @entity3146 1 = 10, @entity3146 2 = 9, and @entity3146 3 = 13). Moreover, 30 @entity5 samples of well-differentiated (grade 1; n = 10), moderate differentiated (grade 2; n = 10), and poorly differentiated (grade 3; n = 10) grading were analyzed. RESULTS: An immunohistochemical staining reaction for inhibin-bA and -bB subunits could be observed in normal and malignant cervical tissue as well as in @entity5 cell lines. Regarding inhibin-bA significant differences were observed between normal tissue and @entity3146 1 and @entity3146 3. Moreover, the immunohistochemical staining reaction for inhibin-bA was significantly higher in @entity3146 3 compared with that in cervical @entity189 grades 1 and 2. The inhibin-bB expression was higher in @entity3146 and @entity5 compared with that in normal cervical tissue. Inhibin-bB was significantly higher in @entity3146 2 and @entity3146 3 compared with @entity5 tissues of histological grade 1. In addition, a significant increase of the staining intensity was observed between @entity5 grades 1 and 2 as well as grade 3. CONCLUSIONS: Both inhibin-b subunits demonstrated a differential expression in @entity3146 and @entity5 , suggesting important roles in cervical @entity105 . Inhibin-bA might be important during progression of @entity3146 , whereas the inhibin-bB subunit could exert a substantial function during differentiation of cervical @entity189 . Moreover, the synthesis of this subunit in cervical @entity189 cell lines also allows the use of this cell line to elucidates their functions in @entity5 pathogenesis.

title: Immunolabeling of the inhibin-bA and -bB subunit in normal and malignant XXXX cervical tissue and @entity5 cell lines.

answer: @entity1 :: (9606,Species) :: ['human']


abstract: AIM: To evaluate the effectiveness and the safety of systemic and intralesional @entity134 therapy for problematic proliferating haemangioma. METHOD: 233 @entity1 with haemangioma were identified from our @entity455 database 1996-2007. 46 (36%) out of 129 @entity1 with proliferating haemangioma required intervention. 24 of these @entity1 received @entity134 therapy. Indications for @entity134 therapy, the response and side effects of treatment and the need for other treatment were recorded. Intralesional @entity2713 up to 4 mg/kg/injection was preferred for small, localised non-periorbital lesions in 5 @entity1 and oral @entity617 2.0-2.5 mg/kg/day was used for larger lesions, especially around the periorbital region in 19 @entity1 . RESULTS: Accelerated regression of the haemangioma was observed in four of the five @entity1 who received intralesional @entity2713 and there was no complication. Overall, the haemangioma in 17 (89%) of the 19 @entity1 responded to high dose oral @entity617 with accelerated regression noted in 10 (53%) @entity1 . Rebound growth was observed in 5 @entity1 during dose tapering, requiring dose increment in three @entity1 and debulking surgery in one @entity1 . Three @entity1 developed @entity851 during treatment but this normalised 3-10 months following cessation of @entity134 therapy. Other side effects included mild @entity154 (n=2), @entity146 (n=2), increased appetite (n=3). CONCLUSION: Intralesional and systemic @entity134 are relatively safe and effective in treating problematic proliferating haemangioma. Systemic @entity134 therapy is associated with few short-term side effects. A multidisciplinary management is essential. @entity1169 is likely to replace @entity134 as the first-line treatment for problematic proliferating haemangioma.

title: XXXX therapy for problematic proliferating haemangioma.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['Cushingoid features']

entities_list: @entity1169 :: ('MESH:D011433', 'Chemical') :: ['Propranolol']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular anomalies']

entities_list: @entity851 :: ('MESH:D006130', 'Disease') :: ['growth retardation']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['irritability']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone']

entities_list: @entity2713 :: ('MESH:D014221', 'Chemical') :: ['triamcinolone']

answer: @entity134 :: (CHEBI:35341,Chemical) :: ['Steroid']


abstract: BACKGROUND: Although no definite risk factors have emerged for the different @entity1583 , a viral cause has been postulated. Several studies have detected SV40 DNA sequences in @entity5 tissues obtained from @entity1893 @entity1 . A link between SV40 and @entity1893 is biologically plausible because SV40 causes @entity1583 in laboratory rodents. METHODS: We investigated 266 Egyptian cases of different @entity1583 , for the presence of SV40 DNA using multiplex nested PCR technique. These cases consisted of 158 @entity1893 ( @entity1893 ), 54 @entity978 ( @entity2033 ), 26 @entity981 ( @entity981 ), 13 @entity3052 ( @entity3052 ), 8 @entity1072 ( @entity1072 ), 7 @entity1860 ( @entity1860 ), in addition to 34 subjects of control group. RESULTS: Our results have shown that SV40 DNA sequences were found in 53.8% of @entity1893 @entity1 , 29.6% of @entity978 @entity1 , and 40.7% of different types of @entity1778 cases. Frequency of SV40 DNA sequences was higher in @entity1893 @entity1 compared to the other @entity5 cases. Also, frequency of SV40 DNA sequences was significantly higher (p<0.05) in @entity1893 @entity1 than in the control group. Regarding the different histological types of @entity1893 , SV40 DNA sequences were detected frequently in diffuse large @entity1892 and in @entity706 . CONCLUSIONS: The present study suggests that SV40 DNA virus is significantly associated with @entity1893 and might have a role in the development of these @entity1583 . Polyomavirus SV40 may act as a cofactor in the pathogenesis of these @entity5 and this could lead to new diagnostic, therapeutic, and preventive approaches.

title: Presence of simian virus 40 DNA sequences in egyptian XXXX with lymphoproliferative disorders.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity981 :: ('MESH:D054198', 'Disease') :: ['ALL', 'acute lymphocytic leukemia']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['follicular lymphoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity1072 :: ('MESH:D015451', 'Disease') :: ['CLL', 'chronic lymphoblastic leukemia']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML']

entities_list: @entity1892 :: ('MESH:D016393', 'Disease') :: ['B-cell lymphoma']

entities_list: @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematological malignancies']

entities_list: @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma", 'NHL', 'non-Hodgkin lymphoma']

entities_list: @entity978 :: ('MESH:D006689', 'Disease') :: ["Hodgkin's disease"]

entities_list: @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML', 'chronic myeloid leukemia']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVE: To compare the three types of urinary diversion namely Ileal Conduit, MAINZ Pouch II and Ileal Neobladder in terms of @entity1 preference, post-operative hospital stay, early and late complications, continence rates, quality of life and @entity1 satisfaction. METHOD: From January 2003 to October 2007, 30 @entity1 (28 males and 2 females) of muscle invasive @entity150 (mean age 57.7 years) were operated upon by radical cysto- prostatectomy or anterior pelvic exenteration and urinary diversion was performed by Ileal conduit, Mainz pouch II or @entity4628 . The @entity1 preference for the type of diversion was determined pre-operatively after discussing all the three types of urinary diversions. Post-operative hospital stay, early and late complications, continence rates, quality of life and @entity1 satisfaction with the type of diversion were evaluated on follow up. RESULTS: 60% of the @entity1 's preferred @entity4628 , 10% preferred Ileal conduit and 10% preferred Mainz pouch II as their 1st choice diversion; 20% left the decision to the operating surgeon. The mean post-operative hospital stay was 15.0 days in Ileal conduit group, 17.8 days in Mainz pouch II group and 19.7 days in @entity4628 group. The mean follow up was 27.7 months. Early complications (within 1 month of surgery) were observed in 46.2% of @entity1 in Ileal conduit group, 38.5% in Mainz pouch II group and 50.0% in @entity4628 group. Late complications (after 1 month of surgery) were seen in 61.5% of @entity1 in Ileal conduit group, 46.2% in Mainz pouch II group and 50.0% in @entity4628 group. In Mainz pouch II group 92.3% of the @entity1 achieved daytime continence and 84.6% achieved night time continence 3 to 6 months after surgery. In @entity4628 group, 75.0% @entity1 achieved day time continence and 50.0% achieved night time continence 3 to 6 months after surgery. @entity1 satisfaction and overall quality of life was described 'Good' by majority of @entity1 in Ileal conduit group and 'Very Good' by majority of @entity1 in Mainz pouch II group and @entity4628 group. CONCLUSION: There are inherited advantages and disadvantages to each form of urinary diversion and @entity1 selection is important to identify the most appropriate method of diversion for an individual.

title: Comparative study of various forms of urinary diversion after radical cystectomy in muscle invasive XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['carcinoma urinary bladder']

entities_list: @entity4628 :: ('MESH:D007077', 'Disease') :: ['Ileal neobladder']

answer: @entity150 :: (MESH:D001749,Disease) :: ['carcinoma urinary bladder']


abstract: An extensive list of side effects and problems are associated with the administration of l-dopa ( @entity3034 ) during treatment of @entity191 . These problems can preclude achieving an optimal response with l-dopa treatment. PURPOSE: To present a case study outlining a novel approach for the treatment of @entity191 that allows for management of problems associated with l-dopa administration and discusses the scientific basis for this treatment. @entity1 AND METHODS: The case study was selected from a database containing 254 @entity191 @entity1 treated in developing and refining this novel approach to its current state. The spectrum of @entity1 comprising this database range from newly diagnosed, with no previous treatment, to those who were diagnosed more than 20 years before and had virtually exhausted all medical treatment options. @entity191 is associated with depletion of @entity669 hydroxylase, @entity935 , @entity750 , and @entity1063 . Exacerbating this is the fact that administration of l-dopa may deplete @entity9109 , @entity9484 , @entity2476 ( @entity2476 ), @entity750 , and @entity17492 . The properly balanced administration of l-dopa in conjunction with @entity2476 , @entity9109 , @entity462 , and cofactors under the guidance of organic cation transporter functional status determination (herein referred to as "OCT assay interpretation") of urinary @entity750 and @entity935 , is at the heart of this novel treatment protocol. RESULTS: When @entity2476 and l-dopa are administered in proper balance along with @entity9109 , @entity462 , and cofactors under the guidance of OCT assay interpretation, the long list of problems that can interfere with optimum administration of l-dopa becomes controllable and manageable or does not occur at all. @entity1 treatment then becomes more effective by allowing the implementation of the optimal dosing levels of l-dopa needed for the relief of symptoms without the dosing value barriers imposed by side effects and adverse reactions seen in the past.

title: Amino acid management of XXXX : a case study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS', 'Patient']

entities_list: @entity3034 :: ('MESH:D007980', 'Chemical') :: ['l-3, 4-dihydroxyphenylalanine']

entities_list: @entity9484 :: ('CHEBI:16828', 'Chemical') :: ['l-tryptophan']

entities_list: @entity462 :: ('MESH:D003545', 'Chemical') :: ['l-cysteine']

entities_list: @entity17492 :: ('MESH:D000603', 'Chemical') :: ['sulfur amino acids']

entities_list: @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease", "Parkinson's"]

entities_list: @entity2476 :: ('CHEBI:28171', 'Chemical') :: ['5-hydroxytryptophan', '5-HTP']

entities_list: @entity9109 :: ('CHEBI:17895', 'Chemical') :: ['l-tyrosine']

entities_list: @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

answer: @entity191 :: (MESH:D010300,Disease) :: ['Parkinson's disease']


abstract: BACKGROUND: Shallow upper buccal sulcus, vertical @entity851 ( @entity85 ), and limited mobility of the median part of the upper lip are among the most common @entity85 following surgical @entity3384 . They are often encountered together as a triad of @entity86 with a common etiology. To date, there has been no surgical procedure to correct these 3 associated deformities in 1 stage. PURPOSE: In this article, we describe the triad above-mentioned 3 associated @entity86 as a single clinical entity, namely the @entity3306 . Moreover, a new procedure for simultaneous correction of these 3 @entity86 in 1 stage is presented. MATERIAL AND METHOD: Over 4 years, this new technique was used in 9 @entity1 , 7 males and 2 females, with the @entity3306 following bilateral @entity3384 repair. The @entity1 were aged from 1 to 3 years. RESULTS: All @entity1 healed uneventfully. A mean follow-up of 18 months revealed a well-contoured upper lip with a sufficient depth of the upper buccal sulcus, an adequate oral sphincter function, and mobility in all @entity1 . The scars placed on the mucosal surface were almost invisible. CONCLUSIONS: Our technique seems to be useful for 1-stage correction of all 3 components of the @entity3306 including shallow upper buccal sulcus, vertical @entity851 of the median part of vermilion, and limited upper lip mobility following surgical repair of the bilateral @entity3384 .

title: Correction of tethered upper @entity3306 following bilateral XXXX repair.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity851 :: ('MESH:D006130', 'Disease') :: ['shortness']

entities_list: @entity3306 :: ('MESH:D008047', 'Disease') :: ['TUL deformity', 'tethered upper lip (TUL) deformity']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative deformities']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['secondary deformities', 'whistling deformity']

entities_list: @entity3384 :: ('MESH:D002971', 'Disease') :: ['cleft lip', 'cleft lips', 'repair of wide bilateral cleft lip']

answer: @entity3384 :: (MESH:D002971,Disease) :: ['cleft lip']


abstract: BACKGROUND: Shallow upper buccal sulcus, vertical @entity851 ( @entity85 ), and limited mobility of the median part of the upper lip are among the most common @entity85 following surgical @entity3384 . They are often encountered together as a triad of @entity86 with a common etiology. To date, there has been no surgical procedure to correct these 3 associated deformities in 1 stage. PURPOSE: In this article, we describe the triad above-mentioned 3 associated @entity86 as a single clinical entity, namely the @entity3306 . Moreover, a new procedure for simultaneous correction of these 3 @entity86 in 1 stage is presented. MATERIAL AND METHOD: Over 4 years, this new technique was used in 9 @entity1 , 7 males and 2 females, with the @entity3306 following bilateral @entity3384 repair. The @entity1 were aged from 1 to 3 years. RESULTS: All @entity1 healed uneventfully. A mean follow-up of 18 months revealed a well-contoured upper lip with a sufficient depth of the upper buccal sulcus, an adequate oral sphincter function, and mobility in all @entity1 . The scars placed on the mucosal surface were almost invisible. CONCLUSIONS: Our technique seems to be useful for 1-stage correction of all 3 components of the @entity3306 including shallow upper buccal sulcus, vertical @entity851 of the median part of vermilion, and limited upper lip mobility following surgical repair of the bilateral @entity3384 .

title: Correction of tethered upper XXXX following bilateral @entity3384 repair.

answer: @entity3306 :: (MESH:D008047,Disease) :: ['lip deformity']


abstract: STUDY DESIGN: Prospective open cohort study. OBJECTIVE: Compare the demographic characteristics and rehabilitation outcomes for both non-traumatic @entity1566 (NT- @entity1566 ) and traumatic @entity1566 (T- @entity1566 ) @entity1 admitted into either specialist @entity1566 rehabilitation units (SCIRUs) or non-specialist rehabilitation units (NSRUs). SETTING: Rehabilitation units in Australia. METHODS: The Australasian Rehabilitation Outcomes Centre maintains a national database on inpatients admitted to most (130/145) public and private rehabilitation units in Australia. @entity1 were included if they had a diagnosis of @entity1566 ( @entity1566 ) and were discharged between 1 January 2006 and 31 December 2006. @entity1 were excluded if admitted for <7 days, only for assessment, or were a readmission following a previous @entity1566 . RESULTS: There were 668 @entity1 with confirmed @entity1566 admitted (NT- @entity1566 n=361, 54.0%; T- @entity1566 n=307, 46.0%). NT- @entity1566 @entity1 were much less likely to be admitted into a specialist SCIRU (30.5%) compared with T- @entity1566 @entity1 (70.4%). For both NT- @entity1566 and T- @entity1566 @entity1 , those admitted to a specialist SCIRU tended to be younger (P=0.000), have a longer length of stay in rehabilitation (P=0.000), and lower Functional Independence Measure (FIM) motor subscale score on admission (P=0.000) than those admitted to a NSRU. For NT- @entity1566 @entity1 , after adjusting for covariates, those admitted into specialist SCIRU had greater improvement in their FIM motor score during rehabilitation. This finding was not demonstrated in T- @entity1566 @entity1 . CONCLUSIONS: There are differences in the characteristics of @entity1566 @entity1 admitted to SCIRU compared with NSRU. NT- @entity1566 @entity1 admitted to SCIRU have greater functional gain.

title: Comparison of XXXX managed in specialised spinal rehabilitation units with those managed in non-specialised rehabilitation units.

entities_list: @entity1566 :: ('MESH:D013119', 'Disease') :: ['spinal cord injury', 'SCI']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Microtubule cytoskeleton is reformed during apoptosis, forming a cortical structure beneath plasma membrane, which plays an important role in preserving cell morphology and plasma membrane integrity. However, the maintenance of the @entity44753 ( @entity44753 ) during apoptosis is not understood. In the present study, we examined apoptosis induced by @entity9800 ( @entity1191 ), a topoisomerase I inhibitor, in @entity1 @entity1 and porcine LLCPK-1a cells. We demonstrate that @entity44753 was organized in apoptotic cells with high @entity855 levels and hyperpolarized mitochondria and, on the contrary, was dismantled in apoptotic cells with low @entity855 levels and mitochondrial depolarization. @entity44753 disorganization after mitochondrial depolarization was associated with increased plasma membrane permeability assessed by enhancing LDH release and increased intracellular @entity460 levels. Living cell imaging monitoring of both, microtubule dynamics and mitochondrial membrane potential, showed that @entity44753 persists during apoptosis coinciding with cycles of mitochondrial hyperpolarization. Eventually, @entity44753 was disorganized when mitochondria suffered a large depolarization and cell underwent secondary @entity39 . @entity44753 stabilization by @entity1311 prevented LDH release and @entity460 influx even though mitochondria were depolarized, suggesting that @entity44753 is essential for plasma membrane integrity. Furthermore, high @entity855 levels and mitochondria polarization collapse after oligomycin treatment in apoptotic cells suggest that @entity855 synthase works in "reverse" mode during apoptosis. These data provide new explanations for the role of @entity44753 and mitochondria during apoptosis.

title: Apoptotic microtubule network organization and maintenance depend on high cellular XXXX levels and energized mitochondria.

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity9800 :: ('MESH:D002166', 'Chemical') :: ['camptothecin']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity44753 :: ('MESH:C567137', 'Disease') :: ['apoptotic microtubule network', 'AMN']

answer: @entity855 :: (MESH:D000255,Chemical) :: ['ATP']


abstract: PURPOSE: The authors sought to evaluate the role of the different imaging techniques in the study of @entity2720 in @entity1 with @entity5145 ( @entity5145 ) and other rheumatic conditions and to assess potential pitfalls in the radiological diagnosis. MATERIALS AND METHODS: Forty-three consecutive @entity1 with @entity6592 as the predominant symptom of a @entity627 were retrospectively studied. Radiography, computed tomography (CT) and magnetic resonance (MR) imaging were performed. The following imaging findings were evaluated: @entity236 , @entity7334 , synovial reaction, joint-space widening, @entity79 or @entity4916 , @entity2001 and, in final stages, joint-space narrowing and @entity3947 . All images were independently reviewed by two musculoskeletal radiologists. RESULTS: Radiography demonstrated @entity79 in 10 @entity1 (23%), @entity2001 in 15 (34%), jointspace widening in 8 (18%), joint-space narrowing in 17 (39%) and @entity3947 in 3 (6%). CT examination showed @entity1463 of the sacroiliac joint in 17 @entity1 (41%), @entity2001 in 21 (53%), joint-space widening in 22 (53%), joint-space narrowing in 18 (43%) and @entity3947 in 7 (17%). At MR, we found @entity236 in 25 @entity1 (92%), @entity7334 in 26 (96%), synovial reaction in 21 (77%) and joint-space widening in 5 (18%). CONCLUSIONS: Radiological study of the @entity2720 in @entity1 with different @entity627 represents a problem of difficult diagnostic evaluation due to the complexity of the anatomical region and the variability of radiographic findings. The integrated use of conventional radiography, CT and MR imaging is suggested to avoid misdiagnosis.

title: Imaging findings of @entity2720 in XXXX and other rheumatic conditions.

entities_list: @entity4916 :: ('MESH:D015576', 'Disease') :: ['hyperostosis']

entities_list: @entity6592 :: ('MESH:D058566', 'Disease') :: ['sacroiliitis']

entities_list: @entity627 :: ('MESH:D012216', 'Disease') :: ['rheumatic disorder', 'rheumatic disorders']

entities_list: @entity3947 :: ('MESH:D000844', 'Disease') :: ['ankylosis']

entities_list: @entity2001 :: ('MESH:D001845', 'Disease') :: ['subchondral erosions']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone sclerosis']

entities_list: @entity1463 :: ('MESH:D012598', 'Disease') :: ['sclerosis']

entities_list: @entity5145 :: ('MESH:D025242', 'Disease') :: ['SpA', 'spondyloarthropathies']

entities_list: @entity7334 :: ('MESH:D057072', 'Disease') :: ['intra-articular effusion']

entities_list: @entity2720 :: ('MESH:D007592', 'Disease') :: ['sacroiliac joints']

entities_list: @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow oedema']

answer: @entity5145 :: (MESH:D025242,Disease) :: ['spondyloarthropathies']


abstract: PURPOSE: The authors sought to evaluate the role of the different imaging techniques in the study of @entity2720 in @entity1 with @entity5145 ( @entity5145 ) and other rheumatic conditions and to assess potential pitfalls in the radiological diagnosis. MATERIALS AND METHODS: Forty-three consecutive @entity1 with @entity6592 as the predominant symptom of a @entity627 were retrospectively studied. Radiography, computed tomography (CT) and magnetic resonance (MR) imaging were performed. The following imaging findings were evaluated: @entity236 , @entity7334 , synovial reaction, joint-space widening, @entity79 or @entity4916 , @entity2001 and, in final stages, joint-space narrowing and @entity3947 . All images were independently reviewed by two musculoskeletal radiologists. RESULTS: Radiography demonstrated @entity79 in 10 @entity1 (23%), @entity2001 in 15 (34%), jointspace widening in 8 (18%), joint-space narrowing in 17 (39%) and @entity3947 in 3 (6%). CT examination showed @entity1463 of the sacroiliac joint in 17 @entity1 (41%), @entity2001 in 21 (53%), joint-space widening in 22 (53%), joint-space narrowing in 18 (43%) and @entity3947 in 7 (17%). At MR, we found @entity236 in 25 @entity1 (92%), @entity7334 in 26 (96%), synovial reaction in 21 (77%) and joint-space widening in 5 (18%). CONCLUSIONS: Radiological study of the @entity2720 in @entity1 with different @entity627 represents a problem of difficult diagnostic evaluation due to the complexity of the anatomical region and the variability of radiographic findings. The integrated use of conventional radiography, CT and MR imaging is suggested to avoid misdiagnosis.

title: Imaging findings of XXXX in @entity5145 and other rheumatic conditions.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity2720 :: (MESH:D007592,Disease) :: ['sacroiliac joints']


abstract: PURPOSE: To evaluate the correlation between quality of vision (QOV) and visual function in @entity726 @entity1 . @entity1 AND METHODS: The relationship between QOV and visual function was investigated in 200 Japanese @entity726 @entity1 . QOV was assessed using the Japanese version of the 25-item National Eye Institute Visual Function Questionnaire. The @entity735 were defined based on the @entity5494 ( @entity5494 ) value of the Humphrey Field Analyzer program 30-2. A single linear regression analysis was applied to assess the relationship. RESULTS: The lowest subscale score was observed in general health followed by general vision and driving. Visual acuity and the central 10   @entity5494 value in the better eye and the central 30   @entity5494 value in the worse eye were highly correlated with QOV. Threshold @entity5494 values at which @entity1 began to have lower QOV ranged from -2 to -12 dB in the better eye and from -7 to -16 dB in the worse eye. CONCLUSION: Loss of visual function in both the better and the worse eye is significantly correlated to QOV. QOV of @entity726 @entity1 begins to decrease in the early stages of @entity227 .

title: Evaluation of the relationship between XXXX in Japanese @entity726 @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual field defects']

entities_list: @entity5494 :: ('MESH:D010262', 'Disease') :: ['MD', 'mean deviation']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma']

entities_list: @entity735 :: ('MESH:D005124', 'Disease') :: ['better eye and the worse eye']

answer: @entity227 :: (MESH:D014786,Disease) :: ['quality of vision and visual function']


abstract: PURPOSE: To evaluate the correlation between quality of vision (QOV) and visual function in @entity726 @entity1 . @entity1 AND METHODS: The relationship between QOV and visual function was investigated in 200 Japanese @entity726 @entity1 . QOV was assessed using the Japanese version of the 25-item National Eye Institute Visual Function Questionnaire. The @entity735 were defined based on the @entity5494 ( @entity5494 ) value of the Humphrey Field Analyzer program 30-2. A single linear regression analysis was applied to assess the relationship. RESULTS: The lowest subscale score was observed in general health followed by general vision and driving. Visual acuity and the central 10   @entity5494 value in the better eye and the central 30   @entity5494 value in the worse eye were highly correlated with QOV. Threshold @entity5494 values at which @entity1 began to have lower QOV ranged from -2 to -12 dB in the better eye and from -7 to -16 dB in the worse eye. CONCLUSION: Loss of visual function in both the better and the worse eye is significantly correlated to QOV. QOV of @entity726 @entity1 begins to decrease in the early stages of @entity227 .

title: Evaluation of the relationship between @entity227 in Japanese XXXX @entity1 .

answer: @entity726 :: (MESH:D005901,Disease) :: ['glaucoma']


abstract: PURPOSE: To evaluate the correlation between quality of vision (QOV) and visual function in @entity726 @entity1 . @entity1 AND METHODS: The relationship between QOV and visual function was investigated in 200 Japanese @entity726 @entity1 . QOV was assessed using the Japanese version of the 25-item National Eye Institute Visual Function Questionnaire. The @entity735 were defined based on the @entity5494 ( @entity5494 ) value of the Humphrey Field Analyzer program 30-2. A single linear regression analysis was applied to assess the relationship. RESULTS: The lowest subscale score was observed in general health followed by general vision and driving. Visual acuity and the central 10   @entity5494 value in the better eye and the central 30   @entity5494 value in the worse eye were highly correlated with QOV. Threshold @entity5494 values at which @entity1 began to have lower QOV ranged from -2 to -12 dB in the better eye and from -7 to -16 dB in the worse eye. CONCLUSION: Loss of visual function in both the better and the worse eye is significantly correlated to QOV. QOV of @entity726 @entity1 begins to decrease in the early stages of @entity227 .

title: Evaluation of the relationship between @entity227 in Japanese @entity726 XXXX .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: The prognosis of @entity1204 is determined in part by stage; endocervical stromal involvement (stage IIB) imparts a worsened prognosis. We describe a deceptive pattern of stage IIB disease that mimics a primary @entity2785 and may lead to understaging of @entity1204 . Fifteen cases of @entity1204 with a peculiar pattern of cervical involvement were identified from our consultation files. All cases were referred in consultation because of doubt about the nature of the cervical process and its relation to the @entity5 ; in a few instances, the cervical proliferation was considered possibly benign and in one case was misinterpreted as @entity1373 . The @entity1 ranged from 49 to 84 years in age (mean age 64.9 years). There was usually a grossly evident @entity1204 . The cervix was unremarkable grossly in at least 11 @entity1 . The cervical @entity5 were composed of variably shaped, often tubular glands with little or no stromal response and mainly invaded as widely spaced glands that often appeared deceptively benign. In 14 cases luminal secretions, mainly eosinophilic, were identified, often leading to consideration of a @entity75 . Ten of the @entity1204 were grade 1, four grade 2, and one grade 3. One was noninvasive, nine superficially invasive, and five deeply invasive. In four cases myoinvasion had, at least in part, a diffusely infiltrative pattern. The @entity5 in the cervix showed no in situ component and no definite surface involvement. Continuity with the @entity5 could be demonstrated in 12 cases. Ten of the cervical @entity5 invaded more deeply than the @entity1204 , four invaded to a similar depth, and only one was more superficial than its endometrial counterpart. The cervical and @entity5 had a similar immunoprofile in nine cases: all were vimentin positive, eight @entity172 positive and one negative, four carcinoembryonic antigen negative, and five with focal apical or rare cytoplasmic staining. This immunoprofile in conjunction with routine morphologic similarity between the two @entity5 and the usual documented continuity between them indicate that the cervical process represents spread from the @entity1204 . It is important for both therapeutic and prognostic reasons that the @entity854 is not misinterpreted as a benign or malignant primary endocervical glandular process.

title: @entity1204 with a deceptive pattern of spread to the uterine cervix: a manifestation of XXXX liable to be misinterpreted as an independent carcinoma or a benign lesion.

entities_list: @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial tumor', 'endometrial endometrioid adenocarcinoma', 'endometrial tumors']

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen']

entities_list: @entity2785 :: ('MESH:D009375', 'Disease') :: ['endocervical glandular proliferation']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['corpus tumors', 'corpus tumor', 'tumors']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['mesonephric lesion']

entities_list: @entity1373 :: ('MESH:D006965', 'Disease') :: ['mesonephric hyperplasia']

entities_list: @entity854 :: ('MESH:D018376', 'Disease') :: ['cervical abnormality']

answer: @entity1204 :: (MESH:D016889,Disease) :: ['stage IIb endometrial carcinoma']


abstract: The prognosis of @entity1204 is determined in part by stage; endocervical stromal involvement (stage IIB) imparts a worsened prognosis. We describe a deceptive pattern of stage IIB disease that mimics a primary @entity2785 and may lead to understaging of @entity1204 . Fifteen cases of @entity1204 with a peculiar pattern of cervical involvement were identified from our consultation files. All cases were referred in consultation because of doubt about the nature of the cervical process and its relation to the @entity5 ; in a few instances, the cervical proliferation was considered possibly benign and in one case was misinterpreted as @entity1373 . The @entity1 ranged from 49 to 84 years in age (mean age 64.9 years). There was usually a grossly evident @entity1204 . The cervix was unremarkable grossly in at least 11 @entity1 . The cervical @entity5 were composed of variably shaped, often tubular glands with little or no stromal response and mainly invaded as widely spaced glands that often appeared deceptively benign. In 14 cases luminal secretions, mainly eosinophilic, were identified, often leading to consideration of a @entity75 . Ten of the @entity1204 were grade 1, four grade 2, and one grade 3. One was noninvasive, nine superficially invasive, and five deeply invasive. In four cases myoinvasion had, at least in part, a diffusely infiltrative pattern. The @entity5 in the cervix showed no in situ component and no definite surface involvement. Continuity with the @entity5 could be demonstrated in 12 cases. Ten of the cervical @entity5 invaded more deeply than the @entity1204 , four invaded to a similar depth, and only one was more superficial than its endometrial counterpart. The cervical and @entity5 had a similar immunoprofile in nine cases: all were vimentin positive, eight @entity172 positive and one negative, four carcinoembryonic antigen negative, and five with focal apical or rare cytoplasmic staining. This immunoprofile in conjunction with routine morphologic similarity between the two @entity5 and the usual documented continuity between them indicate that the cervical process represents spread from the @entity1204 . It is important for both therapeutic and prognostic reasons that the @entity854 is not misinterpreted as a benign or malignant primary endocervical glandular process.

title: XXXX with a deceptive pattern of spread to the uterine cervix: a manifestation of @entity1204 liable to be misinterpreted as an independent carcinoma or a benign lesion.

answer: @entity1204 :: (MESH:D016889,Disease) :: ['Endometrial endometrioid adenocarcinoma']


abstract: PURPOSE: To evaluate the midterm efficacy and safety of the iStent(  ) @entity726 device in @entity1 with secondary @entity1538 . @entity1 AND METHODS: A prospective, nonrandomized, interventional case series involving 10 @entity1 with secondary @entity1538 (traumatic, @entity134 , pseudoexfoliative, and @entity1538 ) of recent onset who underwent ab interno implantation iStent. @entity1 were assessed following the procedure on days 1, 7, and 15 and months 1, 3, 6, and 12, and examinations included visual acuity, intraocular pressure (IOP) measurement using Goldmann tonometry, number of @entity726 medications, and complications. Wilcoxon rank-test for data with abnormal distribution was used for the analysis of IOP and @entity726 medications at baseline versus 3, 6, and 12 months following the procedure. RESULTS: The mean baseline IOP was 26.5    7.9 (range 18-40) mmHg, and significantly decreased in 10.4    9.2 mmHg at three months (P < 0.05), in 7.4    4.9 mmHg at six months (P < 0.05), and in 6.6    5.4 mmHg at 12 months (P < 0.05) following iStent implantation. The mean number of @entity551 medications at baseline was 2.9    0.7 (range 2-4). Statistically significant reductions in the number of medications of 1.1    1.1 were observed at three months (P < 0.05), 1.0    0.7 at six months (P < 0.05), and 1.1    0.6 at 12 months (P < 0.05). No significant changes in visual acuity were noted. The most common complications comprised mild @entity5891 in seven eyes and transient IOP >= 30 mmHg in three eyes on postoperative day 1. Obstruction of the lumen of the stent with a @entity4461 was seen in three eyes, and all instances resolved spontaneously. CONCLUSION: The iStent is a safe and effective treatment option in @entity1 with secondary @entity1538 , and reduces the topical treatment burden in one @entity551 medication.

title: One-year analysis of the iStent trabecular microbypass in secondary XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity1538 :: ('MESH:D005902', 'Disease') :: ['open-angle glaucoma', 'pigmentary glaucoma']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity4461 :: ('MESH:D020141', 'Disease') :: ['blood clot']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotensive']

answer: @entity726 :: (MESH:D005901,Disease) :: ['glaucoma']


abstract: BACKGROUND: Serological proinflammatory markers such as C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) have been associated with reduced survival for many different types of @entity5 . This study determined the prognostic value of the preoperative value of these markers in @entity1 with resectable @entity788 . METHODS: Consecutive @entity1 who underwent pancreaticoduodenectomy for @entity1124 were entered into our database from 2001 to the present day. CRP, NLR, and PLR at the time of presentation were recorded as well as overall and disease-free survival. RESULTS: Seventy-four @entity1 were identified. Overall median survival was 35.0 months and median disease-free survival was 27.0 months. Follow-up ranged from 1 to 125.8 months. Preoperative NLR was significantly greater in those @entity1 who developed recurrence in the follow-up period (4.5 vs. 3.1). CRP and PLR were not found to differ significantly between the two groups. Kaplan-Meier survival analysis of @entity1 with NLR > 5 demonstrated a disease-free survival of 12 months compared with 52 months for those @entity1 with NLR < 5 (p < 0.001). CONCLUSION: Preoperative NLR offers important prognostic information regarding disease-free survival following curative resection of @entity1124 .

title: Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic adenocarcinoma']

entities_list: @entity1124 :: ('MESH:D021441', 'Disease') :: ['pancreatic ductal adenocarcinoma']

answer: @entity788 :: (MESH:D010190,Disease) :: ['pancreatic adenocarcinoma']


abstract: Little is known about the behaviour of @entity320 in @entity1 of mixed ancestry. A retrospective analysis of 844 consecutive @entity1 presenting with @entity320 over a 12-year period was performed. Forty @entity1 (4.8%) were of mixed ancestry. The data evaluated included @entity1 age, gender, delay in presentation, presenting stage, anatomical distribution, histology, management and outcome. The mean age at presentation was 52.8 years. Twenty-seven @entity1 were female. The mean delay in presentation was 1.54 years. Seventy per cent of @entity320 were confined to the extremities, of which one-third were plantar in origin. The most common histological variant, affecting 13 @entity1 (32.5%), was @entity320 ; 12.5% of @entity1 presented with in situ (Stage 0) disease, 17.5% with Stage I disease, 22.5% with @entity34 , 27.5% with @entity5 and 7.5% with Stage IV disease. Twenty-seven @entity1 (67.5%) remained alive at the end of the study after a median follow-up of 5.58 years, whilst 11 (27.5%) died after a median of 2.42 years. The median survival was 3.92 years. Although the histological type and anatomical distribution reflect the disease pattern of black populations, the overall 5-year survival of 74% is similar to that seen in white populations. An education programme is needed to improve @entity320 awareness in mixed race populations.

title: XXXX in South Africans of mixed ancestry: a retrospective analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Stage III disease']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['acral lentiginous melanoma', 'melanoma', 'melanomas']

entities_list: @entity34 :: ('MESH:D016609', 'Disease') :: ['Stage II disease']

answer: @entity320 :: (MESH:D008545,Disease) :: ['Malignant melanoma']


abstract: We report a case of a 14-year- @entity1 who presented to us with a low-grade fever with evening rise for 9 months. Along with this, the @entity1 also reported a reduction in his appetite and body weight. He had a mild dry cough but no respiratory symptoms otherwise. There was no other localization for fever on history. He received antitubercular therapy, based on abnormal chest radiograph. However, there was no relief in his symptoms. General physical examination revealed mild fever. Systemic examination was unremarkable. Blood investigations done for fever were noncontributory. Computed tomographic (CT) scan of the chest revealed a mediastinal mass compressing the @entity825 . The possibilities of @entity5 were considered. A biopsy from the mass under CT guidance was performed. The histopathology revealed multiple epithelioid cell @entity738 with @entity39 , and the diagnosis of @entity378 was made. The clinical course of this @entity1 and the relevant literature is presented in this paper.

title: Anterior mediastinal mass: a rare presentation of XXXX .

entities_list: @entity738 :: ('MESH:D006099', 'Disease') :: ['granulomas']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['lymphoma or germ cell tumour']

entities_list: @entity378 :: ('MESH:D014376', 'Disease') :: ['tuberculosis']

answer: @entity378 :: (MESH:D014376,Disease) :: ['tuberculosis']


abstract: This article attempts to assess the nature, severity and management of the risks associated with pregnancy in @entity740 and @entity454 , including dialysis and transplant recipients. Women with serum @entity1011 levels of >125 mmol/l are at an increased risk for deterioration in renal function, @entity101 with superimposed @entity1468 . Rigid control of @entity101 is crucial for a successful pregnancy outcome. A range of antihypertensive drugs are available with angiotensin converting enzyme inhibitors being contraindicated. @entity1 on dialysis have low fertility rates that return to normal following renal transplantation. Immunosuppresive drugs are not associated with @entity154 . Transplant recipients are at an increased risk for @entity281 that may have implications for the fetus. All groups have an increased risk for @entity3465 and intrauterine growth restriction. The percentage of pregnancies resulting in surviving @entity1 in @entity1 with @entity177 and transplant recipients ranges from 80-100%. For @entity1 who conceive after dialysis, the likelihood of a surviving @entity1 is approximately 50%.

title: XXXX in pregnancy.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Women', 'infants', 'infant']

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['increased congenital anomalies']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity3465 :: ('MESH:C536271', 'Disease') :: ['prematurity']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['chronic renal insufficiency']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal insufficiency']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity1468 :: ('MESH:D011225', 'Disease') :: ['pre-eclampsia and obstetric complications']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease']

answer: @entity740 :: (MESH:D051436,Disease) :: ['Chronic renal insufficiency']


abstract: OBJECTIVE: Clinical study and follow up of @entity1737 @entity1 in Oman. METHODS: Follow up of 50 consecutive @entity1737 @entity1 referred to the Sultan Qaboos University Hospital, Oman for a median period of 3 years from 1997 to 2000. We based the diagnosis on the clinical picture, repetitive nerve stimulation tests and edrophonium test. We performed a computerized tomography scan of the chest and anti- @entity934 receptor antibodies. We reviewed the results of immuno modulatory treatment including thymectomy and compared these with other studies. RESULTS: Of 50 @entity1 , 6 had purely @entity1737 . Of the 44 with generalized @entity1737 , 28 had bulbar involvement and 12 required ventilatory support. Eight out of 29 thymectomized @entity1 had drug free remission after 2 years. There was worsening of @entity1109 in only one out of 8 pregnancies and deliveries. CONCLUSION: Bulbar and ventilatory involvement are more common in our series as compared with western data. Pregnancy and delivery were well tolerated.

title: Clinical profile of XXXX in the Sultanate of Oman.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1109 :: ('MESH:D012678', 'Disease') :: ['myasthenic symptoms']

entities_list: @entity1737 :: ('MESH:D009157', 'Disease') :: ['myasthenia', 'ocular myasthenia', 'myasthenia gravis']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']

answer: @entity1737 :: (MESH:D009157,Disease) :: ['myasthenia gravis']


abstract: In @entity0 @entity1 , several regimens of neoadjuvant chemotherapy have been developed in order to achieve prognostic advantages for individual @entity1 . Though some percentages of @entity0 @entity1 show clinically complete response to neoadjuvant chemotherapy, the histopathological specimens of these @entity1 demonstrate a considerably high frequency of the existence of @entity66 . In this study, we aimed to evaluate the therapeutic effect of neoadjuvant chemotherapy for @entity0 @entity1 showing clinically complete response (cCR) to neoadjuvant chemotherapy, using thin-section (5 mm) helical CT (prone position) with bolus injection of contrast agent. Between April 1994 and March 2002, 9 @entity1 with @entity0 showing cCR to the neoadjuvant chemotherapy, who had undergone thin-section CT study both before and following neoadjuvant chemotherapy, enrolled in the study. The mean age of the @entity1 was 46.2 years and all of them were female. The clinical stages were, 8 @entity1 in stage II, and one in stage IIIA. In the CT evaluation, @entity66 was visualized in 5 out of the 9 @entity1 . Histopathological examination disclosed the existence of @entity5 in 6 out of the 9 @entity1 , but only non-invasive @entity5 was revealed in 1 out of the 6. As @entity1 having @entity66 composed only of non-invasive @entity5 are classified into the pathologically complete response group according to the WHO classification, 4 out of these 9 @entity1 showing clinically complete response to the neoadjuvant chemotherapy were classified into pCR (pathologically complete response) group, and another 5 were classified into the @entity11595 (pathologically partial response) group. As a result, the diagnostic accuracy of the second CT study performed after neoadjuvant chemotherapy was evaluated as 77.8%, with a sensitivity of 80.0%, a specificity of 75.0%, a positive predictive value ( @entity2286 ) of 80.0%, and a negative predictive value (NPV) of 75.0%. Therefore, for precise evaluation of the neoadjuvant chemotherapeutic effect for @entity0 , thin-section CT studies are considered to be essential.

title: CT findings of XXXX with clinically complete response following neoadjuvant chemotherapy--histological correlation.

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'residual cancers']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: OBJECTIVE: The purpose of the study was to investigate the prevalence of @entity5052 in morbidly @entity28 subjects before and after Roux-en-Y gastric bypass (RYGBP) and its relationship with @entity209 . SUBJECTS AND METHOD: We evaluated 420 morbidly @entity28 @entity1 . Pre and postoperative (8 months after RYGBP) blood samples were drawn. @entity28 @entity1 underwent laparoscopic RYGBP and after eight months all the tests were repeated. RESULTS: The overall prevalence of @entity5052 was 34.28%. @entity5052 was more common in @entity1 than in @entity1 (51.72 vs. 29.72%; p = 0.0002). @entity1 with @entity5052 were more likely to have @entity6 (p = 0.034) and more elevated fasting plasma @entity413 levels (p = 0.027). @entity1 with @entity5052 were more likely to have @entity101 (p = 0.003), @entity209 (p = 0.001), elevated @entity1674 (p = 0.001) and GGT (p = 0.009), and decreased HDL (p = 0.011). After surgery, @entity414 levels decreased from 5.60    1.28 to 4.23    1.20 (p < 0.0001). The prevalence of @entity5052 decreased from 33.6% to 6.4% (p < 0.0001), in @entity1 from 48.3% to 17.2% (p < 0.0001) and in @entity1 from 29.7% to 3.6% (p < 0.0001). CONCLUSION: Concentrations of @entity414 were associated with the prevalence of @entity209 in this sample of morbidly @entity28 @entity1 . Also, @entity353 after RYGBP can reduce @entity414 levels and the prevalence of @entity5052 .

title: Relation of XXXX with components of @entity209 before and after Roux-en-Y gastric bypass in morbidly @entity28 subjects.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Women', 'Men', 'men']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'Obese']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity5052 :: ('MESH:D033461', 'Disease') :: ['hyperuricemia', 'Hyperuricemia']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome', 'metabolic abnormalities', 'metabolic syndrome abnormalities']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity414 :: ('MESH:D014527', 'Chemical') :: ['uric acid']

answer: @entity414 :: (MESH:D014527,Chemical) :: ['uric acid']


abstract: OBJECTIVE: The purpose of the study was to investigate the prevalence of @entity5052 in morbidly @entity28 subjects before and after Roux-en-Y gastric bypass (RYGBP) and its relationship with @entity209 . SUBJECTS AND METHOD: We evaluated 420 morbidly @entity28 @entity1 . Pre and postoperative (8 months after RYGBP) blood samples were drawn. @entity28 @entity1 underwent laparoscopic RYGBP and after eight months all the tests were repeated. RESULTS: The overall prevalence of @entity5052 was 34.28%. @entity5052 was more common in @entity1 than in @entity1 (51.72 vs. 29.72%; p = 0.0002). @entity1 with @entity5052 were more likely to have @entity6 (p = 0.034) and more elevated fasting plasma @entity413 levels (p = 0.027). @entity1 with @entity5052 were more likely to have @entity101 (p = 0.003), @entity209 (p = 0.001), elevated @entity1674 (p = 0.001) and GGT (p = 0.009), and decreased HDL (p = 0.011). After surgery, @entity414 levels decreased from 5.60    1.28 to 4.23    1.20 (p < 0.0001). The prevalence of @entity5052 decreased from 33.6% to 6.4% (p < 0.0001), in @entity1 from 48.3% to 17.2% (p < 0.0001) and in @entity1 from 29.7% to 3.6% (p < 0.0001). CONCLUSION: Concentrations of @entity414 were associated with the prevalence of @entity209 in this sample of morbidly @entity28 @entity1 . Also, @entity353 after RYGBP can reduce @entity414 levels and the prevalence of @entity5052 .

title: Relation of @entity414 with components of @entity209 before and after Roux-en-Y gastric bypass in morbidly XXXX subjects.

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

answer: @entity28 :: (MESH:D009765,Disease) :: ['obese']


abstract: OBJECTIVE: The purpose of the study was to investigate the prevalence of @entity5052 in morbidly @entity28 subjects before and after Roux-en-Y gastric bypass (RYGBP) and its relationship with @entity209 . SUBJECTS AND METHOD: We evaluated 420 morbidly @entity28 @entity1 . Pre and postoperative (8 months after RYGBP) blood samples were drawn. @entity28 @entity1 underwent laparoscopic RYGBP and after eight months all the tests were repeated. RESULTS: The overall prevalence of @entity5052 was 34.28%. @entity5052 was more common in @entity1 than in @entity1 (51.72 vs. 29.72%; p = 0.0002). @entity1 with @entity5052 were more likely to have @entity6 (p = 0.034) and more elevated fasting plasma @entity413 levels (p = 0.027). @entity1 with @entity5052 were more likely to have @entity101 (p = 0.003), @entity209 (p = 0.001), elevated @entity1674 (p = 0.001) and GGT (p = 0.009), and decreased HDL (p = 0.011). After surgery, @entity414 levels decreased from 5.60    1.28 to 4.23    1.20 (p < 0.0001). The prevalence of @entity5052 decreased from 33.6% to 6.4% (p < 0.0001), in @entity1 from 48.3% to 17.2% (p < 0.0001) and in @entity1 from 29.7% to 3.6% (p < 0.0001). CONCLUSION: Concentrations of @entity414 were associated with the prevalence of @entity209 in this sample of morbidly @entity28 @entity1 . Also, @entity353 after RYGBP can reduce @entity414 levels and the prevalence of @entity5052 .

title: Relation of @entity414 with components of XXXX before and after Roux-en-Y gastric bypass in morbidly @entity28 subjects.

answer: @entity209 :: (MESH:D008659,Disease) :: ['metabolic syndrome']


abstract: Gut-derived endotoxin and pathogenic bacteria have been proposed to be important causative factors of morbidity and mortality due to @entity64 . However, the molecular mechanisms underlying the small @entity1944 caused by @entity64 have yet to be well characterized. In order to verify the possible inflammatory pathogenesis of intestinal tissue injury, a @entity19 @entity64 model was established. Cooling treatment was applied, mimicking the clinical therapy. Morphologic changes in intestinal tissue and 10 cytokines and chemokines produced from ileum tissue were detected, and their correlation was analyzed. As a result, @entity1944 in @entity19 worsened with the increase in rectal core temperature (Tc) during heat stress. When heat stress was halted at a Tc of no more than 41  C followed by cooling treatment, pathological recovery from the @entity66 was observed. However, when cooling treatment was applied after the Tc reached 42  C, the lesions continuously deteriorated until the animals succumbed. The levels of pro-inflammatory ( @entity635 , @entity2047 , @entity777 and @entity637 ) and anti-inflammatory ( @entity1618 , @entity12782 ) cytokines showed significant changes at different time points during the heat stress and cooling treatment, but no changes in @entity2304 , @entity8929 , @entity12427 and @entity58 were observed. Levels of @entity635 , @entity1618 and @entity12782 were moreover significantly correlated with @entity1944 scores. A significant inverse linear correlation was observed between @entity1944 and @entity12782 levels. In conclusion, this study provided insight into the inflammatory pathogenesis of intestinal tissue injury after heat stress and cooling treatment in a @entity19 model, and presented a potential biomarker for the evaluation of @entity1944 during @entity64 .

title: Intestinal inflammation and tissue injury in response to heat stress and cooling treatment in XXXX .

entities_list: @entity1944 :: ('MESH:D007410', 'Disease') :: ['intestinal lesions', 'intestinal injury']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['heat stroke']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['injury of heat stress']

answer: @entity19 :: (10090,Species) :: ['mice']


abstract: @entity354 ( @entity354 ) is a very common disorder. Therapeutic options include lifestyle modifications, medical therapy, laparoscopic antireflux surgery, and three more recent options-injection therapy to the lower esophageal sphincter, endoscopic sewing procedures, and radio frequency ablation therapy. Medical therapy is effective in most @entity1 but not always successful with advanced disease. Up to 70% of subjects do not have adequate nocturnal control of gastric acid secretion with 20 mg of @entity4546 given twice per day. @entity1 who do not tolerate medical therapy, who respond inadequately, or who want to avoid life-long drug therapy are candidates for alternate treatments. Studies on endoscopic procedures such as polymethylmethacrylate ( @entity4625 ) injection, the Stretta procedure,and endoscopic suturing techniques all suffer from having small study groups for each procedure,unknown durability, short follow-up, and the absence of randomized, controlled procedures. Limitations on endoscopic techniques are @entity4423 , severe @entity2910 , and larger @entity357 . Laparoscopic antireflux surgery remains a well-established, durable alternative to long-term medical therapy. It has the benefits of convenience, safety, minimal complications, improved quality of life, and low cost. Alternative methods will have to earn their place against this gold standard.

title: [Treatment strategies for XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis']

entities_list: @entity357 :: ('MESH:D006551', 'Disease') :: ['hiatal hernias']

entities_list: @entity354 :: ('MESH:D005764', 'Disease') :: ['Gastroesophageal reflux disease', 'GERD']

entities_list: @entity4423 :: ('MESH:D015154', 'Disease') :: ['esophageal motility disorders']

entities_list: @entity4546 :: ('MESH:D009853', 'Chemical') :: ['omeprazole']

answer: @entity354 :: (MESH:D005764,Disease) :: ['gastroesophageal reflux disease']


abstract: OBJECTIVE: To examine whether erectile functioning after termination of @entity7855 intake in @entity1 with psychogenic @entity323 ( @entity323 ) can be predicted with psychological measures. METHOD: The subjects in a nonrandomized controlled trial were 65 heterosexual @entity1 with acquired psychogenic @entity323 , aged 54.2 +/- 11 years. @entity7855 medication was taken as required before sexual activity, up to two times per week. Response to a global end point question ("Did the treatment you took during the study improve your physical response during sexual activity in the last 4 weeks?") was recorded after 6 weeks of @entity7855 use and, subsequently, 6 weeks without medication. Other measures of sexual functioning and cognitive predictor measures were also administered. RESULTS: Of the 65 @entity1 who commenced @entity7855 treatment, 37% withdrew from the study before follow-up assessment. At posttreatment, 89% of @entity1 reported that treatment had improved or cured their erectile functioning. At follow-up, 66% of @entity1 had maintained posttreatment gains. Response at follow-up could be predicted (p <.001) with 96% sensitivity and 50% specificity by entering changes in sexual self-confidence and the @entity1 's rating of his partner's wish to continue treatment in a logistic regression model. Higher odds for recovery of erectile functioning were found in @entity1 reporting increased sexual self-confidence and the estimation that their partner wanted them to continue @entity7855 use. High pretreatment sexual desire was found to further increase the odds for positive responding at follow-up. CONCLUSIONS: The present results indicate that continued improvement of erectile functioning is possible after discontinuation of @entity7855 use in @entity1 with psychogenic @entity323 . Maintenance of gains can be predicted from cognitive changes before medication is withdrawn.

title: Cognitive changes predict continued recovery of erectile functioning versus relapse after discontinuation of @entity7855 treatment for XXXX .

entities_list: @entity7855 :: ('MESH:C101426', 'Chemical') :: ['sildenafil', 'Sildenafil']

entities_list: @entity1 :: ('9606', 'Species') :: ['men', 'participants', 'participant']

entities_list: @entity323 :: ('MESH:D007172', 'Disease') :: ['erectile dysfunction', 'ED']

answer: @entity323 :: (MESH:D007172,Disease) :: ['male erectile dysfunction']


abstract: OBJECTIVE: To examine whether erectile functioning after termination of @entity7855 intake in @entity1 with psychogenic @entity323 ( @entity323 ) can be predicted with psychological measures. METHOD: The subjects in a nonrandomized controlled trial were 65 heterosexual @entity1 with acquired psychogenic @entity323 , aged 54.2 +/- 11 years. @entity7855 medication was taken as required before sexual activity, up to two times per week. Response to a global end point question ("Did the treatment you took during the study improve your physical response during sexual activity in the last 4 weeks?") was recorded after 6 weeks of @entity7855 use and, subsequently, 6 weeks without medication. Other measures of sexual functioning and cognitive predictor measures were also administered. RESULTS: Of the 65 @entity1 who commenced @entity7855 treatment, 37% withdrew from the study before follow-up assessment. At posttreatment, 89% of @entity1 reported that treatment had improved or cured their erectile functioning. At follow-up, 66% of @entity1 had maintained posttreatment gains. Response at follow-up could be predicted (p <.001) with 96% sensitivity and 50% specificity by entering changes in sexual self-confidence and the @entity1 's rating of his partner's wish to continue treatment in a logistic regression model. Higher odds for recovery of erectile functioning were found in @entity1 reporting increased sexual self-confidence and the estimation that their partner wanted them to continue @entity7855 use. High pretreatment sexual desire was found to further increase the odds for positive responding at follow-up. CONCLUSIONS: The present results indicate that continued improvement of erectile functioning is possible after discontinuation of @entity7855 use in @entity1 with psychogenic @entity323 . Maintenance of gains can be predicted from cognitive changes before medication is withdrawn.

title: Cognitive changes predict continued recovery of erectile functioning versus relapse after discontinuation of XXXX treatment for @entity323 .

answer: @entity7855 :: (MESH:C101426,Chemical) :: ['sildenafil']


abstract: Brain imaging studies have long supported that @entity161 is a @entity75 , involving many discrete and widely spread regions. Generally, studies have shown decreases in cortical @entity62 ( @entity62 ) volume. Here, we selectively review recent papers studying @entity62 volume changes in @entity161 subjects, both first-episode (FE) and chronic, in an attempt to quantify and better understand differences between healthy and @entity1 groups. We focused on the cortical @entity62 of the prefrontal cortex, limbic and paralimbic structures, temporal lobe, and one subcortical structure (the caudate nucleus). We performed a search of the electronic journal database PsycINFO using the keywords " @entity161 " and "MRI," and selected for papers published between 2001 and 2008. We then screened for only those studies utilizing manual or manually edited tracing methodologies for determining regions of interest (ROIs). Each region of interest was indexed independently; thus, one paper might yield results for numerous brain regions. Our review found that in almost all ROIs, cortical @entity62 volume was decreased in the @entity1 populations. The only exception was the caudate nucleus - most studies reviewed showed no change, while one study showed an increase in volume; this region, however, is particularly sensitive to medication effects. The reductions were seen in both FE and chronic @entity161 . These results clearly support that @entity161 is an anatomical @entity75 , and specifically that @entity161 @entity1 tend to have decreased cortical @entity62 in regions involved in higher cognition and emotional processing. That these reductions were found in both FE and chronic subjects supports that @entity75 are present at the onset of illness, and are not simply a consequence of chronicity. Additional studies assessing morphometry at different phases of the illness, including prodromal stages, together with longitudinal studies will elucidate further the role of progression in this disorder.

title: A selective review of volumetric and morphometric imaging in XXXX .

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['brain abnormalities', 'disorder of the brain']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity62 :: ('MESH:D056784', 'Disease') :: ['gray matter', 'GM']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia']

answer: @entity161 :: (MESH:D012559,Disease) :: ['schizophrenia']


abstract: BACKGROUND: Stenosis of the @entity8 ( @entity23067 -TRAS) is an uncommon cause of @entity813 and @entity101 . We assessed the role of duplex sonography (DS) in regard to clinical and angiographic findings and followed the @entity1 after percutaneous transluminal angioplasty ( @entity865 ), @entity865 stenting (PTAS), or surgery. METHODS: From January 1988 to August 2001, 97 of 1,064 kidney recipients underwent angiography for clinical or Doppler-sonographic suspicion of vascular problems. Kidney function, blood pressure, medication, and DS findings after renal transplantation (RTx) at the time of diagnosis of @entity23067 -TRAS and after treatment were evaluated. RESULTS: @entity23067 -TRAS was diagnosed in 16 @entity1 (1.5%) (49.6+/-6.9 years). Four @entity1 demonstrated early presentation of @entity23067 -TRAS 1 to 7 days after RTx (group A), leading to @entity810 but without @entity101 . In all @entity1 , DS revealed pulsus parvus et tardus, low pulsatility index (PI) (<1.0), and a pathologic flow profile in the iliac artery proximal and distal to the graft. After treatment (surgery in two @entity1 , @entity865 in one @entity1 , PTAS in one @entity1 ), all @entity1 developed @entity177 ( @entity1011 1.7+/-0.9 mg/dL). PI increased from 0.9+/-0.1 to 1.2+/-0.1 (P=0.04), and flow profile within the iliac artery distal to the graft normalized. Late presentation (3-209 months after RTx) of @entity23067 -TRAS was observed in 12 @entity1 (group B), causing an increase of @entity1011 in 11 @entity1 (two @entity1 receiving dialysis treatments), @entity551 (141+/-15 and 80.7+/-7 to 160+/-18 and 85+/-7 mm Hg, P=0.009), and an increase in antihypertensive drugs (2.1+/-1.1 and 4.3+/-1, P=0.003) in all @entity1 . The PI was decreased when compared with values early after RTx (1.6+/-0.4 to 1.2+/-0.3, P=0.007), and flow profile in the iliac artery was pathologic. All @entity1 except one were managed by surgery (n=6), @entity865 (n=1), or PTAS (n=4). @entity1011 (2.7+/-1.4 to 1.8+/-0.4 mg/dL, P=0.02) and blood pressure (160+/-18/85+/-7 mm Hg to 138+/-7/82+/-9, P=0.018) improved. Antihypertensive drugs were reduced to 2.8+/-0.8 (P=0.01). PI increased from 1.2+/-0.3 to 1.9+/-0.5 (P=0.01). Flow profile within the iliac artery distal to the graft anastomosis normalized. Kidney function, blood pressure, and PI remained unchanged during follow-up (82+/-69.9 months) in both groups. CONCLUSIONS: @entity23067 -TRAS is rare. Because clinical symptoms are similar to those of transplant @entity2791 , DS is a valuable tool for diagnosis and follow-up for this type of @entity455 . Selective treatment with @entity865 , PTAS, or surgery improves kidney function and @entity101 .

title: XXXX proximal to a kidney transplant: clinical findings, duplex-sonographic criteria, treatment, and outcome.

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['iliac segment proximal to the transplant renal artery']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular lesion']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity2791 :: ('MESH:D012078', 'Disease') :: ['renal artery stenosis']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['good renal function']

entities_list: @entity810 :: ('MESH:D058186', 'Disease') :: ['acute renal failure']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['Creatinine', 'creatinine']

entities_list: @entity813 :: ('MESH:D055031', 'Disease') :: ['graft dysfunction']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['impairment of blood pressure']

answer: @entity2791 :: (MESH:D012078,Disease) :: ['Iliac artery stenosis']


abstract: To clarify clinicopathologic features of @entity1689 with lymphoplasmacytic infiltration, we carried out a study of 35 cases. There were two histologic groups, which we have designated lymphoplasmacytic sclerosing @entity788 and @entity1689 . Lymphoplasmacytic sclerosing @entity788 (22 cases) was a fibrosing process with diffuse lymphoplasmacytic infiltrates involving pancreatic lobules and ducts, adipose tissue, blood vessels, and common bile duct. Obliterative @entity3527 was found in every case except for one. The histologic features were similar to other @entity74 , and one @entity1 also had retroperitoneal @entity82 . Affected @entity1 tended to be elderly @entity1 . @entity1689 (13 cases) was characterized by inflammatory infiltrates (including neutrophils) that were denser in the lobules than in interlobular fibrotic areas. Neutrophils were also prominent in the ducts, and destruction of the duct epithelium was commonly seen. @entity1 ages were more broadly distributed than in lymphoplasmacytic sclerosing @entity788 . Two @entity1 had @entity29 . We conclude that @entity1689 with lymphoplasmacytic infiltration, sometimes called autoimmune @entity788 , consists of at least two different processes. One of these, lymphoplasmacytic sclerosing @entity788 , is a histologically unique lesion and could be a pancreatic manifestation of @entity74 .

title: XXXX with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient', 'men']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity1689 :: ('MESH:D050500', 'Disease') :: ['Idiopathic duct-centric chronic pancreatitis', 'idiopathic duct-centric chronic pancreatitis', 'idiopathic chronic pancreatitis']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['idiopathic fibrosclerosing disorders']

entities_list: @entity3527 :: ('MESH:D010689', 'Disease') :: ['phlebitis']

answer: @entity1689 :: (MESH:D050500,Disease) :: ['Idiopathic chronic pancreatitis']